Integrated Glycoproteomics Demonstrates Fucosylated Serum Paraoxonase 1 Alterations in Small Cell Lung Cancer

Small cell lung cancer (SCLC) is an aggressive type of lung cancer, and the detection of SCLCs at an early stage is necessary for successful therapy and for improving cancer survival rates. Fucosylation is one of the most common glycosylation-based modifications. Increased levels of fucosylation have been reported in a number of pathological conditions, including cancers. In this study, we aimed to identify and validate the aberrant and selective fucosylated glycoproteins in the sera of patients with SCLC. Fucosylated glycoproteins were enriched by the Aleuria aurantia lectin column after serum albumin and IgG depletion. In a narrowed down and comparative data analysis of both label-free proteomics and isobaric peptide-tagging chemistry iTRAQ approaches, the fucosylated glycoproteins were identified as up- or down-regulated in the sera of limited disease and extensive disease stage patients with SCLC. Verification was performed by multiple reaction monitoring-mass spectrometry to select reliable markers. Four fucosylated proteins, APCS, C9, SERPINA4, and PON1, were selected and subsequently validated by hybrid A. aurantia lectin ELISA (HLE) and Western blotting. Compared with Western blotting, the HLE analysis of these four proteins produced more optimal diagnostic values for SCLC. The PON1 protein levels were significantly reduced in the sera of patients with SCLC, whereas the fucosylation levels of PON1 were significantly increased. Fucosylated PON1 exhibited an area under curve of 0.91 for the extensive disease stage by HLE, whereas the PON1 protein levels produced an area under curve of 0.82 by Western blot. The glycan structural analysis of PON1 by MS/MS identified a biantennary fucosylated glycan modification consisting of a core + 2HexNAc + 1Fuc at increased levels in the sera of patients with SCLC. In addition, the PON1 levels were decreased in the sera of the Lewis lung carcinoma lung cancer mouse model that we examined. Our data suggest that fucosylated protein biomarkers, such as PON1, and their fucosylation levels and patterns can serve as diagnostic and prognostic serological markers for SCLC.

[1]  W. Travis,et al.  Pulmonary neuroendocrine tumors: What (little) do we know? , 2006, Journal of the National Comprehensive Cancer Network : JNCCN.

[2]  B. La Du,et al.  Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. , 1998, The Journal of clinical investigation.

[3]  E. Miyoshi,et al.  Fucosylation and gastrointestinal cancer. , 2010, World journal of hepatology.

[4]  J. Dennis,et al.  Glycoprotein glycosylation and cancer progression. , 1999, Biochimica et biophysica acta.

[5]  R Apweiler,et al.  On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database. , 1999, Biochimica et biophysica acta.

[6]  A. Kobata,et al.  Altered glycosylation of proteins produced by malignant cells, and application for the diagnosis and immunotherapy of tumours , 2005, Immunology and cell biology.

[7]  U. Förstermann,et al.  Beyond reduction of atherosclerosis: PON2 provides apoptosis resistance and stabilizes tumor cells , 2011, Cell Death and Disease.

[8]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[9]  P. Durrington,et al.  Paraoxonase prevents accumulation of lipoperoxides in low‐density lipoprotein , 1991, FEBS letters.

[10]  M. Akçay,et al.  Serum paraoxonase levels in gastric cancer. , 2003, Hepato-gastroenterology.

[11]  H. Ryoo,et al.  Identification of putative serum glycoprotein biomarkers for human lung adenocarcinoma by multilectin affinity chromatography and LC‐MS/MS , 2007, Proteomics.

[12]  L. Chao,et al.  Inhibition of experimental lung metastasis by systemic lentiviral delivery of kallistatin , 2010, BMC Cancer.

[13]  Yehia Mechref,et al.  High-throughput solid-phase permethylation of glycans prior to mass spectrometry. , 2008, Rapid communications in mass spectrometry : RCM.

[14]  R. Aebersold,et al.  A statistical model for identifying proteins by tandem mass spectrometry. , 2003, Analytical chemistry.

[15]  J. Dennis,et al.  Complex N-Glycan Number and Degree of Branching Cooperate to Regulate Cell Proliferation and Differentiation , 2007, Cell.

[16]  Y. Levo,et al.  Serum Amyloid P‐Component Levels in Patients with Malignancy , 1986, Scandinavian journal of immunology.

[17]  R. Simon,et al.  Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  J. Dennis,et al.  Regulation of Cytokine Receptors by Golgi N-Glycan Processing and Endocytosis , 2004, Science.

[19]  S. Hirohashi,et al.  Biological, pathological and clinical features of small cell lung cancer. , 1986, Cancer letters.

[20]  K. Baggerly,et al.  Evaluation of changes in serum protein profiles during neoadjuvant chemotherapy in HER2‐positive breast cancer using an LC‐MALDI‐TOF/MS procedure , 2010, Proteomics.

[21]  H. Çelik,et al.  Assessment of serum paraoxonase and arylesterase activity in patients with endometrial cancer. , 2009, European journal of gynaecological oncology.

[22]  I. Kątnik-Prastowska,et al.  Terminal monosaccharide expression on amniotic glycoproteins as biomarkers of fetus maturity. , 2011, Biochemical Society transactions.

[23]  W. Ha,et al.  The differential proteome profile of stomach cancer: identification of the biomarker candidates. , 2004, Oncology research.

[24]  K. Ha,et al.  Fucosylated glycoproteomic approach to identify a complement component 9 associated with squamous cell lung cancer (SQLC). , 2011, Journal of proteomics.

[25]  J. Sandoval,et al.  Serum protein profiling to identify high-risk neuroblastoma: preclinical relevance of blood-based biomarkers. , 2007, The Journal of surgical research.

[26]  Alexey I Nesvizhskii,et al.  Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. , 2002, Analytical chemistry.

[27]  C. Rudin,et al.  Novel systemic therapies for small cell lung cancer. , 2008, Journal of the National Comprehensive Cancer Network : JNCCN.

[28]  R. Angeletti,et al.  Altered protein expression at early-stage rat hepatic neoplasia. , 2007, American journal of physiology. Gastrointestinal and liver physiology.

[29]  J. Lowe,et al.  Fucose: biosynthesis and biological function in mammals. , 2003, Glycobiology.

[30]  T. Nakagawa,et al.  Biological function of fucosylation in cancer biology. , 2007, Journal of biochemistry.

[31]  M. Akçay,et al.  Serum paraoxonase levels in pancreatic cancer. , 2003, Hepato-gastroenterology.

[32]  M. Pepys,et al.  Demonstration of amyloid A (AA) protein and amyloid P component (AP) in deposits of systemic amyloidosis associated with renal adenocarcinoma , 1983, The Journal of pathology.

[33]  J. Minna,et al.  Biological heterogeneity of small cell lung cancer. , 1985, Seminars in oncology.

[34]  Keiko Hata,et al.  Sialidase and malignancy: A minireview , 2003, Glycoconjugate Journal.

[35]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[36]  Xian Jiang,et al.  Combining kallistatin gene therapy and meloxicam to treat hepatocellular carcinoma in mice , 2009, Cancer science.

[37]  R. Kannagi,et al.  Carbohydrate‐mediated cell adhesion in cancer metastasis and angiogenesis , 2004, Cancer science.

[38]  L. Tse,et al.  Adeno‐associated virus‐mediated expression of kallistatin suppresses local and remote hepatocellular carcinomas , 2008, The journal of gene medicine.

[39]  J. Borlak,et al.  A 2‐DE MALDI‐TOF study to identify disease regulated serum proteins in lung cancer of c‐myc transgenic mice , 2009, Proteomics.

[40]  M. Korbelik,et al.  Dying cells program their expedient disposal: serum amyloid P component upregulation in vivo and in vitro induced by photodynamic therapy of cancer. , 2007, Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology.

[41]  D. Shih,et al.  PON3 is upregulated in cancer tissues and protects against mitochondrial superoxide-mediated cell death , 2012, Cell Death and Differentiation.

[42]  G. Gao,et al.  Kallikrein-binding protein inhibits growth of gastric carcinoma by reducing vascular endothelial growth factor production and angiogenesis , 2007, Molecular Cancer Therapeutics.

[43]  A. Kobata.  Altered glycosylation of surface glycoproteins in tumor cells and its clinical application. , 1989, Pigment cell research.

[44]  M. Bochaton-Piallat,et al.  HDL-associated paraoxonase-1 can redistribute to cell membranes and influence sensitivity to oxidative stress. , 2011, Free radical biology & medicine.

[45]  S. Hakomori,et al.  Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. , 1989, Advances in cancer research.

[46]  S. Tannenbaum,et al.  Comparative time-dependent analysis of potential inflammation biomarkers in lymphoma-bearing SJL mice. , 2007, Journal of proteome research.

[47]  So-Young Park,et al.  Evaluation of plasma carcinogenic markers in rat hepatic tumors models induced by rat hepatoma N1-S1 cells and benzo[a]pyrene , 2010, Archives of pharmacal research.

[48]  J. Szymendera.  Clinical usefulness of three monoclonal antibody-defined tumor markers: CA 19-9, CA 50, and CA 125. , 1986, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[49]  Yin-kun Liu,et al.  Serum paraoxonase 1 heteroplasmon, a fucosylated, and sialylated glycoprotein in distinguishing early hepatocellular carcinoma from liver cirrhosis patients. , 2012, Acta biochimica et biophysica Sinica.

[50]  Fucosylation Index of α‐Fetoprotein, a Possible Aid in the Early Recognition of Hepatocellular Carcinoma in Patients with Cirrhosis , 1993, Hepatology.

[51]  Szymendera Jj.  Clinical usefulness of three monoclonal antibody-defined tumor markers: CA 19-9, CA 50, and CA 125. , 1986 .

[52]  H. Çelik,et al.  Serum paraoxonase and arylesterase activities in patients with epithelial ovarian cancer. , 2009, Gynecologic oncology.

[53]  C. Bessant,et al.  i-Tracker: For quantitative proteomics using iTRAQ™ , 2005, BMC Genomics.

[54]  S. Koca,et al.  Serum paraoxonase and arylesterase activities in patients with lung cancer in a Turkish population , 2007, BMC Cancer.